What happens when a landmark Alzheimer’s study turns out to contain manipulated scientific images?
In 2006, an influential study helped strengthen the case for a particular form of amyloid-beta as a contributor to memory loss.
In 2024, that study was officially retracted following serious concerns about its images and the reliability of its findings.
Let that sink in.
Meanwhile, billions of dollars have been invested in Alzheimer’s treatments targeting amyloid plaques.
But here’s the question that fascinates me:
Are we so focused on treating what’s visible in the brain that we’re overlooking what’s happening metabolically throughout the body?
Insulin resistance, metabolic dysfunction, inflammation, and impaired brain energy metabolism all deserve serious scientific investigation.
And this raises another uncomfortable question: When pharmaceutical companies invest billions in a particular theory, how difficult does it become to challenge that theory?
To be clear, one retracted study doesn’t invalidate all Alzheimer’s research. But it should make us question how science establishes its priorities.
In this week’s Subconscious Fat video, I explore the Alzheimer’s research scandal, the pharmaceutical industry’s focus on plaques, and the metabolic questions that deserve far more attention.
Because sometimes the most important scientific breakthrough begins by questioning what everyone else takes for granted.
Watch the video and tell me what you think.
Other links related to this post:
What If Alzheimer’s Is Really a Problem With Brain Fuel?
